11 / 15
Volume 2, Issue 3 2017
Journal of Medical Oncology and Therapeutics
Dermatologists & Melanoma 2017
August 31-September 01, 2017
Page 81
&
2
nd
Euro-Global Congress on
August 31-September 01, 2017 London, UK
12
th
Global Dermatologists Congress
Melanoma and Skin Diseases
Most current and up to date treatment options for non-melanoma skin cancers
Neil Sandhu
Daystar Skin and Cancer Center USA
N
on-melanoma skin cancer (NMSC) is the most common type of cancer amongst the Caucasian population. Basal cell
carcinoma and squamous cell carcinoma are the two types of non-melanoma skin cancers. These skin cancers require
treatment with Mohs Surgery, excision, superficial radiotherapy, cryosurgery, Electrodessication and curettage, Blu-U light
treatment Imiquimod, or 5-Flurouracil. Mohs surgery is the most effective treatment for all types of BCC and SCC greater than
2cm in diameter. Mohs surgery cure rate is 97% for SCC and 99% for BCC. Standard excisions are performed on BCC and
SCC less than 2 cm in diameter. The cure rate for a standard excision is 98% for BCC and 95% for SCC. Electrodissection and
cautery is performed by using a sharp ring curette instrument to remove the epidermis and dermis that contains cancer cells.
Then you use electrocautery to char the base of the wound. This is best used to treat low risk NMSC. Superficial radiotherapy
is a noninvasive low energy radiotherapy that penetrates only a short distance below the surface of the skin. This is best for
people who are not candidates for surgery. Cryotherapy involves using a device that sprays liquid nitrogen to freeze and then
thaw the areas of concern causing a local cellular destruction. This is used for superficial BCC and in situ SCC. Imiquimoid and
topical 5-Fluorouracil (5FU) are best used for superficial BCC but not for SCC. Lastly, the Blu-U light treatment is best used
for actinic keratosis (AK), which is pre-cancerous. After application of Levulan Kerastick to the AKs, exposure to the Blu light
causes a reaction to occur which destroys the AK cells.
sandhu.neil@gmail.comJ Med Oncl Ther 2017, 2:3